Herpes Zoster Reactivation in Patients with Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs

Arthritis Care and Research

Volumn 67, Issue 12, 2015, Pages 1671-1678

  Pappas, Dimitrios A ^a,b   Hooper, Michele M ^c   Kremer, Joel M ^b,d   Reed, George ^b,e   Shan, Ying ^b   Wenkert, Deborah ^c   Greenberg, Jeffrey D ^b,f   Curtis, Jeffrey R ^g  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b Departments of Biostatistics and Epidemiology and Outcomes Research   (United States)

^c AMGEN INC   (United States)

^d ALBANY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; RHEUMATOID ARTHRITIS; TIME TO TREATMENT; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; AGE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOGENICITY; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; UNITED STATES; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDNISONE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; VIRUS ACTIVATION;

EID: 84956695614     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22628     Document Type: Article

References (31)

1. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al., The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007; 57: 1431-8.
2. Gnann JW Jr, Whitley RJ., Clinical practice: Herpes zoster. N Engl J Med 2002; 347: 340-6.
3. Schmader K., Herpes zoster in older adults. Clin Infect Dis 2001; 32: 1481-6.
4. Hope-Simpson RE., The nature of herpes zoster. Practitioner 1964; 193: 217-9.
5. Choo PW, Donahue JG, Manson JE, Platt R., The epidemiology of varicella and its complications. J Infect Dis 1995; 172: 706-12.
6. Wolfe F, Michaud K, Chakravarty EF., Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006; 45: 1370-5.
7. Thomas SL, Hall AJ., What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4: 26-33.
8. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al., Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127: 305-14.
9. Arvin A., Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005; 352: 2266-7.
10. Bowsher D., Postherpetic neuralgia and its treatment: A retrospective survey of 191 patients. J Pain Symptom Manage 1996; 12: 290-9.
11. Straus SE, Ostrove JM, Inchauspe G, Felser JM, Freifeld A, Croen KD, et al., Varicella-zoster virus infections: Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108: 221-37.
12. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al., Recommendations for the management of herpes zoster. Clin Infect Dis 2007; Suppl 1: S1-26.
13. Veenstra J, Krol A, van Praag RM, Frissen PH, Schellekens PT, Lange JM, et al., Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995; 9: 1153-8.
14. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R, et al., Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166: 1153-6.
15. Guinee VF, Guido JJ, Pfalzgraf KA, Giacco GG, Lagarde C, Durand M, et al., The incidence of herpes zoster in patients with Hodgkin's disease: An analysis of prognostic factors. Cancer 1985; 56: 642-8.
16. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA., The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20: 748-53.
17. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al., Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNFα agents. JAMA 2009; 301: 737-44.
18. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, et al., Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309: 887-95.
19. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al., Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48: 1364-71.
20. Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS., Incidence and time trends of herpes zoster in rheumatoid arthritis: A population-based cohort study. Arthritis Care Res (Hoboken) 2013; 65: 854-61.
21. Harpaz R, Ortega-Sanchez IR, Seward JF., Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57 (RR-5): 1-30.
22. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al., Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72: 229-34.
23. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al., Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-9.
24. Aletaha D, Smolen J., The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 Suppl: S100-8.
25. Thomas SL, Heck RH., Analysis of large scale secondary data in higher education research: Potential perils associated with complex sampling designs. Res High Educ 2001; 42: 517-40.
26. Luo Z, Gardiner JC, Bradley CJ., Applying propensity score methods in medical research: Pitfalls and prospects. Med Care Res Rev 2010; 67: 528-54.
27. Austin PC., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
28. Donahue JG, Choo PW, Manson JE, Platt R., The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605-9.
29. Di Luzio Paparatti U, Arpinelli F, Visona G., Herpes zoster and its complications in Italy: An observational survey. J Infect 1999; 38: 116-20.
30. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al., Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20.
31. Kremer JM, Greenberg J., Interpreting registry-derived drug studies: Does societal context matter? [editorial]. Arthritis Rheum 2009; 60: 3155-7.